These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 22584132)

  • 1. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
    DeVries JH; Bain SC; Rodbard HW; Seufert J; D'Alessio D; Thomsen AB; Zychma M; Rosenstock J;
    Diabetes Care; 2012 Jul; 35(7):1446-54. PubMed ID: 22584132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
    Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
    J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
    Davies M; Heller S; Sreenan S; Sapin H; Adetunji O; Tahbaz A; Vora J
    Diabetes Care; 2013 May; 36(5):1368-76. PubMed ID: 23275363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
    Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q
    Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
    Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
    Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Nauck M; Frid A; Hermansen K; Thomsen AB; During M; Shah N; Tankova T; Mitha I; Matthews DR
    Diabetes Obes Metab; 2013 Mar; 15(3):204-12. PubMed ID: 22985213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
    Rodbard HW; Bode BW; Harris SB; Rose L; Lehmann L; Jarlov H; Thurman J;
    Diabet Med; 2017 Feb; 34(2):189-196. PubMed ID: 27589252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.
    Meneghini L; Mersebach H; Kumar S; Svendsen AL; Hermansen K
    Endocr Pract; 2011; 17(5):727-36. PubMed ID: 21550957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study.
    Kesavadev J; Joshi SR
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):28-30. PubMed ID: 24482985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
    Aroda VR; Bailey TS; Cariou B; Kumar S; Leiter LA; Raskin P; Zacho J; Andersen TH; Philis-Tsimikas A
    Diabetes Obes Metab; 2016 Jul; 18(7):663-70. PubMed ID: 26990378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.